SCHEMBL5544675

SCHEMBL5544675

[CH2]c1ccccc1NCc1ccc(Br)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
AGER Q15109 1/20 0.44
THRB P10828 1/20 0.44
ALOX12 P18054 1/20 0.44
L3MBTL1 Q9Y468 5/20 0.44
HSD17B10 Q99714 3/20 0.43
APP P05067 2/20 0.42
GAA P10253 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HPGD P15428 2/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538885 0.84 HSD17B10 (0.59) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5534733 0.81 KCNH3 (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5542578 0.81 HTT (0.52) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5539503 0.81 MAPT (0.55) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5546124 0.81 KDM4E (0.44) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5541606 0.81 PARP1 (0.50) MAPTKDM4EALDH1A1HSD17B10APP
SCHEMBL22796037 0.78 MAPT (0.73) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL13908182 0.78 MAPT (0.44) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5542641 0.77 EPHX2 (0.47) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5537509 0.77 NPC1 (0.50) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.